38 related articles for article (PubMed ID: 38755279)
1. Effect of atorvastatin versus placebo on efficacy in patients with diffuse large B-cell lymphoma receiving R-CHOP.
Nemec R; Scherrer-Crosbie M; Abramson JS; Redd R; Gilman HK; Ho T; Wu J; Heemelaar J; Neuberg D; Hochberg EP; Barnes JA; Armand P; Jacobsen ED; Jacobson CA; Kim AI; Friedman RS; LaCasce AS; Neilan TG; Soumerai JD
Leuk Lymphoma; 2024 Jun; 65(6):783-788. PubMed ID: 38380861
[TBL] [Abstract][Full Text] [Related]
2. A prospective randomized controlled clinical trial investigating the efficacy of low-dose olanzapine in preventing nausea and vomiting associated with oxaliplatin-based and irinotecan-based chemotherapy.
Shen J; Zhao J; Jin G; Li H; Jiang Y; Wu Y; Gao J; Chen F; Li J; Wang W; Li Q
J Cancer Res Clin Oncol; 2024 May; 150(5):283. PubMed ID: 38806870
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the Efficacy and Safety of Palonosetron Hydrochloride in Preventing Nausea And Vomiting After TACE: A Retrospective Analysis.
Lu H; Zheng C; Liang B; Xia X
Curr Radiopharm; 2024; 17(1):46-54. PubMed ID: 38037910
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of netupitant/palonosetron in preventing nausea and vomiting in diffuse large B cell lymphoma patients undergoing R-CHOP chemotherapy.
Kwak K; Park Y; Kim BS; Kang KW
Sci Rep; 2024 May; 14(1):11229. PubMed ID: 38755279
[TBL] [Abstract][Full Text] [Related]
5. Dexamethasone-sparing on days 2-4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial).
Minatogawa H; Izawa N; Shimomura K; Arioka H; Iihara H; Sugawara M; Morita H; Mochizuki A; Nawata S; Mishima K; Tsuboya A; Miyaji T; Honda K; Yokomizo A; Hashimoto N; Yanagihara T; Endo J; Kawaguchi T; Furuya N; Sone Y; Inada Y; Ohno Y; Katada C; Hida N; Akiyama K; Ichikura D; Konomatsu A; Ogura T; Yamaguchi T; Nakajima TE
Br J Cancer; 2024 Feb; 130(2):224-232. PubMed ID: 37973958
[TBL] [Abstract][Full Text] [Related]
6. Netupitant-palonosetron (NEPA) for Preventing Chemotherapy-induced Nausea and Vomiting: From Clinical Trials to Daily Practice.
Aapro M; Jordan K; Scotté F; Celio L; Karthaus M; Roeland E
Curr Cancer Drug Targets; 2022; 22(10):806-824. PubMed ID: 35570542
[TBL] [Abstract][Full Text] [Related]
7. One-Day Versus Three-Day Dexamethasone with NK1RA for Patients Receiving Carboplatin and Moderate Emetogenic Chemotherapy: A Network Meta-analysis.
Watanabe D; Iihara H; Fujii H; Makiyama A; Nishida S; Suzuki A
Oncologist; 2022 Jun; 27(6):e524-e532. PubMed ID: 35427418
[TBL] [Abstract][Full Text] [Related]
8. Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020-2025.
Kanas G; Ge W; Quek RGW; Keeven K; Nersesyan K; Jon E Arnason
Leuk Lymphoma; 2022 Jan; 63(1):54-63. PubMed ID: 34510995
[TBL] [Abstract][Full Text] [Related]
9. Antiemetics: ASCO Guideline Update.
Hesketh PJ; Kris MG; Basch E; Bohlke K; Barbour SY; Clark-Snow RA; Danso MA; Dennis K; Dupuis LL; Dusetzina SB; Eng C; Feyer PC; Jordan K; Noonan K; Sparacio D; Lyman GH
J Clin Oncol; 2020 Aug; 38(24):2782-2797. PubMed ID: 32658626
[TBL] [Abstract][Full Text] [Related]
10. Increasing Incidence of B-Cell Non-Hodgkin Lymphoma and Occurrence of Second Primary Malignancies in South Korea: 10-Year Follow-up Using the Korean National Health Information Database.
Kim JS; Liu Y; Ha KH; Qiu H; Rothwell LA; Kim HC
Cancer Res Treat; 2020 Oct; 52(4):1262-1272. PubMed ID: 32599988
[TBL] [Abstract][Full Text] [Related]
11. Real-world evidence of NEPA, netupitant-palonosetron, in chemotherapy-induced nausea and vomiting prevention: effects on quality of life.
Karthaus M; Oskay-Özcelik G; Wülfing P; Hielscher C; Guth D; Zahn MO; Flahaut E; Schilling J
Future Oncol; 2020 May; 16(14):939-953. PubMed ID: 32298187
[No Abstract] [Full Text] [Related]
12. NEPA efficacy and tolerability during (neo)adjuvant breast cancer chemotherapy with cyclophosphamide and doxorubicin.
Yeo W; Lau TK; Kwok CC; Lai KT; Chan VT; Li L; Chan V; Wong A; Soo WM; Yeung EW; Wong KH; Tang NL; Suen JJ; Mo FK
BMJ Support Palliat Care; 2022 Jul; 12(e2):e264-e270. PubMed ID: 31996363
[TBL] [Abstract][Full Text] [Related]
13. Granisetron plus aprepitant versus granisetron in preventing nausea and vomiting during CHOP or R-CHOP regimen in malignant lymphoma: a retrospective study.
Wakasugi Y; Noda S; Ikuno Y; Horie M; Kito K; Minamiguchi H; Terada T
J Pharm Health Care Sci; 2019; 5():24. PubMed ID: 31832222
[TBL] [Abstract][Full Text] [Related]
14. A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC).
Zhang L; Lu S; Feng J; Dechaphunkul A; Chang J; Wang D; Chessari S; Lanzarotti C; Jordan K; Aapro M
Ann Oncol; 2018 Feb; 29(2):452-458. PubMed ID: 29092012
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of aprepitant for CHOP chemotherapy-induced nausea, vomiting, and anorexia.
Morita M; Kishi S; Ookura M; Matsuda Y; Tai K; Yamauchi T; Ueda T
Curr Probl Cancer; 2017; 41(6):419-425. PubMed ID: 29061362
[TBL] [Abstract][Full Text] [Related]
16. A prospective study of palonosetron for prevention of chemotherapy-induced nausea and vomiting in malignant lymphoma patients following highly emetogenic chemotherapy.
Takahashi T; Okada T; Ikejiri F; Ito S; Okada Y; Takahashi F; Kumanomido S; Jo Y; Adachi K; Onishi C; Kawakami K; Miyake T; Inoue M; Suzuki R; Suzumiya J
Int J Clin Oncol; 2018 Feb; 23(1):189-194. PubMed ID: 28823027
[TBL] [Abstract][Full Text] [Related]
17. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients.
Roila F; Molassiotis A; Herrstedt J; Aapro M; Gralla RJ; Bruera E; Clark-Snow RA; Dupuis LL; Einhorn LH; Feyer P; Hesketh PJ; Jordan K; Olver I; Rapoport BL; Roscoe J; Ruhlmann CH; Walsh D; Warr D; van der Wetering M;
Ann Oncol; 2016 Sep; 27(suppl 5):v119-v133. PubMed ID: 27664248
[No Abstract] [Full Text] [Related]
18. 2016 US lymphoid malignancy statistics by World Health Organization subtypes.
Teras LR; DeSantis CE; Cerhan JR; Morton LM; Jemal A; Flowers CR
CA Cancer J Clin; 2016 Nov; 66(6):443-459. PubMed ID: 27618563
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
